LIVE ATTENUATED MUMPS VIRUS VACCINE. II. EARLY CLINICAL STUDIES

Publisher Website
Google Scholar
Abstract
Groups of children in institutions who were initially without mumps antibody were inoculated subcutaneously with twelfth chick embryo and chick embryo cell culture passage (level A) or seventeenth passage (level B) Jeryl Lynn strain mumps virus vaccine. All children developed mumps antibody following inoculation of either strain. The level A vaccine, however, was insufficiently attenuated for routine immunization, since roughly 25% of the vaccine recipients developed parotitis and excreted mumps virus. Children who received B level virus failed to develop fever or parotitis or any other significant clinical reaction to the vaccine and serum amylase values were not significantly altered. Mumps neutralizing antibody persisted for at least 7 months following vaccine B, the longest period tested. A study among children in a community showed that as little as 317 50% tissue culture infectivity doses of virus in level B vaccine induced neutralizing antibody in 100% of children vaccinated. The B level vaccine proved entirely safe and highly effective in inducing protective antibody against mumps.

This publication has 0 references indexed in Scilit: